Skip to main content

Site notifications

YSELTY (Theramex Australia Pty Ltd)

Product name
YSELTY
Date registered
Evaluation commenced
Decision date
Approval time
174 (175 working days)
Active ingredients
linzagolix choline
Registration type
NCE/NBE
Indication

YSELTY is indicated for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids.

Help us improve the Therapeutic Goods Administration site